NBIX Neurocrine Biosciences, Inc.

156.59USD-3.85%Mkt Cap: 15.85B USDP/E: 23.23

Neurocrine Biosciences, Inc. discovers, develops, and commercialize pharmaceuticals for neurological, psychiatric, endocrine, and immunological disorders in the United States and internationally. The company's products i…

Insiders, last 90 daysNet sellers
Institutional holders20 on file

Key Statistics

Company
Market Cap15.85B USD
Enterprise Value16.20B USD
Revenue (TTM)3.70B USD
Gross Profit2.81B USD
Net Income (TTM)478.60M USD
Revenue/Share36.73 USD
Last Price156.59 USD
Fiscal Year EndDec 2025
MR QuarterSep 2026
Employees2.5K
CountryUS
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
ISIN—
Valuation
P/E (Trailing)23.23
P/E (Forward)12.73
PEG0.32
EV/EBITDA15.15
EV/Revenue4.38
P/S4.28
P/B4.09
EPS (TTM)6.74 USD
EPS (Forward)12.30 USD
52W Range
122.1454% of range186.12
52W High186.12 USD
52W Low122.14 USD
Profitability
Gross Margin98.18%
Oper. Margin26.62%
EBITDA Margin28.88%
Profit Margin16.73%
ROE14.71%
ROA10.33%
ROIC19.74%
ROCE16.37%
Growth
Revenue Growth41.20%
Earnings Growth-3.90%
Cash Flow & Leverage
Operating CF782.70M USD
CapEx (TTM)34.00M USD
FCF Margin27.51%
FCF Yield6.42%
Net Debt-286.10M USD
Net Debt/EBITDA-0.27
Net Debt/FCF-0.28
Balance Sheet
Debt/Equity0.13
Current Ratio2.04
Quick Ratio1.72
Book Value/Sh38.29 USD
Cash/Share7.29 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div DateDec 29, 1995
Pay Date—
Analyst Consensus
Rating1.4 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)208.54 USD
Upside (mean)+33.2%
Target Range150.00 USD – 253.00 USD
150.00+33.2% to mean253.00
# Analysts28
Ownership
Shares Out.101.22M
Float99.90M
Insiders1.08%
Institutions104.93%
Short Interest
Short Ratio4.5d
Short % Float7.58%
Short % Out.5.83%
Shares Short5.90M
Short (prev mo.)5.85M
Technical
SMA 50148.77 (+5.3%)
SMA 200149.02 (+5.1%)
Beta0.33
S&P 52W Chg12.08%
Avg Vol (30d)1.37M
Avg Vol (10d)1.72M
Technical Indicators
RSI (14)49.1
MACD4.8355
MACD Signal5.3850
MACD Hist.-0.5494
BB Upper179.88 USD
BB Middle158.66 USD
BB Lower137.43 USD
BB Width26.75%
ATR (14)5.446 USD
Vol Ratio (20d)0.92x

About Neurocrine Biosciences (NASDAQ: NBIX)

›

Neurocrine Biosciences (NASDAQ: NBIX) is listed on Nasdaq, where its shares trade in USD. It belongs to the Drug Manufacturers - Specialty & Generic industry, part of the Healthcare sector, and reports about 2,500 employees.

The shares were at 156.59 USD on 19 November 2026, up 1.2% over 52 weeks. Its 52-week range is 122.14 USD to 186.12 USD: the price is 15.9% below the high and 28.2% above the low.

At a market capitalisation of 15.85B USD, it trades at 23.2 times trailing earnings and 12.7 times forward earnings. The median trailing P/E of its 17 largest Drug Manufacturers - Specialty & Generic peers is 26.3, a discount of 12% for NBIX.

Neurocrine Biosciences reports return on equity of 14.7%, an operating margin of 26.6% and revenue up 41.2% year over year.

It holds more cash than debt, a net cash position of 286.10M USD. Its Piotroski F-score is 6 out of 9, an average reading of its financial health. 28 analysts cover the stock, with an average rating of Strong Buy; their mean price target of 208.54 USD is 33.2% above the current price. The next earnings report is expected on 11 February 2027.